Search Results for "Asahi Kasei A Bpep"

22:05 EDT 27th May 2016 | BioPortfolio

Matching Channels


Matching News

Asahi Kasei Seeks European Expansion

Japan’s Asahi Kasei has set up a German subsidiary based in Düsseldorf as a springboard for further expansion in Europe. Asahi Kasei Europe will start trading on Apr. 1 with a market capitaliza...

Asahi Kasei licenses Asian rights to Array's ARRY954 in pain, inflammation

Asahi Kasei Corp.'s Asahi Kasei Pharma Corp. division will develop and commercialize Array BioPharma Inc.'s tropomyosin receptor kinase A (TrkA) inhibitors for pain, inflammation, and other indication...

Array BioPharma links with Asahi Kasei on TrkA inhibitors

Array BioPharm and Japan’s Asahi Kasei Pharma Corp have entered a strategic collaboration to develop…

Array BioPharma to collaborate with Asahi Kasei on pain treatments

Array BioPharma will partner with Asahi Kasei Pharma on the development and marketing of its tropomyosin receptor kinase A in -More- 

PeptiDream in research collaboration with Asahi Kasei Pharma

Asahi Kasei Pharma has become the latest company to join forces with PeptiDream in a research deal.

Array BioPharma, Asahi Kasei Pharma collaborate for novel pain and inflammation program

Array BioPharma and Asahi Kasei Pharma announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for p...

BRIEF-Array Biopharma and Asahi Kasei Pharma announce collaboration for pain and inflammation program

* Co, Asahi Kasei Pharma corporation announce development and commercialization collaboration for novel pain and inflammation program

Asahi Kasei Pharma, RaQualia deal

Matching PubMed Articles

Blood Pressure Effects of Yoga, Alone or in Combination With Lifestyle Measures: Results of the Lifestyle Modification and Blood Pressure Study (LIMBS).

The authors conducted a study to assess the effects of yoga on blood pressure (BP). Patients were randomized to yoga (Blood Pressure Education Program [BPEP]), or a combined program (COMBO). Ambulator...

Initial Experience With the Gaia Composite Core Guidewires in Coronary Chronic Total Occlusion Crossing.

Inability to cross the occlusion with a guidewire is the most common cause of failure of coronary chronic total occlusion (CTO) interventions. We describe two cases of successful application of the no...

C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus.

In this study, we investigate how measures of insulin secretion and other clinical information affect long-term glycemic control in patients with type 2 diabetes mellitus. Between October 2012 and Jun...

Search Whole site using Google

Quick Search
Advertisement Advertisement